Dexcom G7 Continuous Glucose Monitoring System Gets Regulatory Nod From Health Canada

DexCom, Inc.'s DXCM next-generation Dexcom G7 Continuous Glucose Monitoring System has been approved by Health Canada. This department operates under the Government of Canada and is responsible for national health policy.

Dexcom G7 can warn of high or low glucose levels with a predictive urgent low alert to help avoid potentially dangerous hypoglycemic events. The company said the regulatory nod gives Canadians access to a technology that reduces hospitalizations and emergency room visits due to hypoglycemia by up to 42%. 

Also Read: DexCom Revises 2025 Outlook, Announces New Product For Diabetics

"Dexcom G7 builds on the innovation that our previous CGM systems have brought to the lives of Canadians," said André Côté, Vice President and General Manager of Dexcom Canada. 

Through remote monitoring and reporting capabilities, users can also share information with family, loved ones and care teams anywhere, anytime.

While Health Canada approves, Dexcom G7 has yet to be made available for purchase. Dexcom G7 is expected to be launched in Canada by the end of 2023.

"With approval of Dexcom G7, the newest glucose sensor to come to Canada, patients will have a new, simple to start and easy to use tool in their diabetes management toolbox..," said Alice Cheng, Endocrinologist at Trillium Health Partners, Credit Valley Hospital and St. Michael's Hospital.

Price Action: DXCM shares are trading flat at $127.02 in the premarket session on the last check Wednesday.